Curković Bozidar
Medicinski fakultet, Sveuciliste u Zagrebu, Salata 3, 10000 Zagreb.
Reumatizam. 2011;58(2):65-8.
The objectives of treatment of spondyloarthritis are to improve functional status, diminish pain, prevent structural deterioration and reach drug free remission of disease. Nonsteroidal antiinflammatory drugs are the cornerstone of pharmacological intervention for ankylosing spondylitis, rapidly reducing pain and stiffness, and possibly modifying natural course of disease when given continuously. Conventional disease-modifying antirheumatic drugs which have been shown to be effective in the treatment of rheumatoid arthritis, have no proven such efficacy in spondyloarthritis. TNF-alpha blockade is highly effective in targeting the different disease features (axial disease, peripheral arthritis, enthesitis, and extra-articular features such as psoriasis or uveitis). There is no current evidence for the efficacy of other biological therapies in ankylosing spondylitis and psoriatic arthritis and every effort must be made to use TNF-alpha antagonists optimally.
脊柱关节炎的治疗目标是改善功能状态、减轻疼痛、防止结构恶化并实现疾病的药物停用缓解。非甾体抗炎药是强直性脊柱炎药物干预的基石，能迅速减轻疼痛和僵硬，持续使用时可能改变疾病的自然进程。已证明对类风湿关节炎有效的传统抗风湿药物，在脊柱关节炎中尚无经证实的此类疗效。肿瘤坏死因子-α阻断剂在针对不同疾病特征（轴性疾病、外周关节炎、附着点炎以及如银屑病或葡萄膜炎等关节外特征）方面非常有效。目前没有证据表明其他生物疗法对强直性脊柱炎和银屑病关节炎有效，必须尽一切努力优化使用肿瘤坏死因子-α拮抗剂。
